Richard Daniell - Mar 6, 2023 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Role
Exec. VP, European Commercial
Signature
/s/ Dov Bergwerk as attorney-in-fact for Richard Daniell
Stock symbol
TEVA
Transactions as of
Mar 6, 2023
Transactions value $
-$687,949
Form type
4
Date filed
3/8/2023, 03:02 PM
Previous filing
Mar 7, 2023
Next filing
Feb 1, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TEVA Ordinary Shares Sale -$179K -18K -12.7% $9.93 124K Mar 6, 2023 Direct F1, F2, F3
transaction TEVA Ordinary Shares Sale -$509K -54K -43.63% $9.43 69.8K Mar 7, 2023 Direct F1, F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2 The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.86 to $10.045, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.37 to $9.725, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.